Literature DB >> 16425963

Maedi-visna virus and its relationship to human immunodeficiency virus.

Halldor Thormar1.   

Abstract

Maedi-visna is a slow virus infection of sheep leading to a progressing lymphoproliferative disease which is invariably fatal. It affects multiple organs, but primarily the lungs where it causes interstitial pneumonia (maedi). Infection of the central nervous system was commonly observed in Icelandic sheep (visna), infection of mammary glands (hard udder) in sheep in Europe and the USA, and infection of the joints in sheep in the USA. The name ovine progressive pneumonia (OPP) is commonly used in the USA and ovine lentivirus (OvLV) infection is also a name used for maedi-visna. A related infection of goats, caprine arthritis-encephalitis (CAE), is common in Europe and the USA. The natural transmission of maedi-visna is mostly by the respiratory route, but also to newborn lambs by colostrum and milk. Intrauterine transmission seems to be rare and venereal transmission is not well documented. Macrophages are the major target cells of maedi-visna virus (MVV), but viral replication is greatly restricted in the animal host, apparently due to a posttranscriptional block. The low-grade viral production in infected tissues can explain the slow course of the disease in sheep. The lesions in maedi-visna consist of infiltrates of lymphocytes, plasma cells, and macrophages, and are detectable shortly after experimental transmission. Several studies indicate that the lesions are immune mediated and that cytotoxic T-lymphocytes may be important effector cells. The persistence of the MVV infection is explained by a reservoir of latently infected blood and bone marrow monocytes, which migrate into the target organs and mature into macrophages with proviral DNA transcription, but limited replication of virus. The MVV particles are morphologically similar to those of other retroviruses and the mode of replication follows the same general pattern. The genome organization and gene regulation resembles that of other lentiviruses. In addition to gag, pol and env, MVV has three auxiliary genes (tat, rev and vif), which seem to have similar functions as in other lentiviruses, with a possible exception of the tat gene. A determination of the 9200 nucleotide sequence of the MVV genome shows a close relationship to CAE virus, but limited sequence homology with other lentiviruses, and only in certain conserved domains of the reverse transcriptase and possibly in the surface protein. MVV infection in sheep and HIV-1 infection in humans have a number of features in common such as a long preclinical period following transmission, and a slow development of multiorgan disease with fatal outcome. A brief early acute phase, which is terminated by the immune response, is also an interesting common feature. Like HIV-1, MVV is macrophage tropic and the early stages of the HIV-1 infection which affect the central nervous system and the lungs are in many ways comparable to maedi-visna. In contrast to HIV-1, MVV does not infect T-lymphocytes and does not cause T-cell depletion and immunodeficiency. This is responsible for the difference in the late stages of the HIV-1 and MVV infections and the final clinical outcome. Despite limited sequence homology, certain proteins of MVV and HIV-1 show structural and functional similarities. Studies of MVV may therefore help in the search for new drugs against lentiviruses, including HIV-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425963

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  22 in total

1.  Herd risk factors associated with sero-prevalence of Maedi-Visna in the Manitoba sheep population.

Authors:  Muhammad Shuaib; Chris Green; Mamoon Rashid; Glen Duizer; Terry L Whiting
Journal:  Can Vet J       Date:  2010-04       Impact factor: 1.008

2.  Perivascular inflammatory cells in ovine Visna/maedi encephalitis and their possible role in virus infection and lesion progression.

Authors:  Laura Polledo; Jorge González; Julio Benavides; Beatriz Martínez-Fernández; Ma Carmen Ferreras; Juan F García Marín
Journal:  J Neurovirol       Date:  2012-10-18       Impact factor: 2.643

Review 3.  Strategies to inhibit viral protein nuclear import: HIV-1 as a target.

Authors:  Aviad Levin; Abraham Loyter; Michael Bukrinsky
Journal:  Biochim Biophys Acta       Date:  2010-08-16

4.  The Role of Animal Research in Pandemic Responses.

Authors:  Jacqueline K Brockhurst; Jason S Villano
Journal:  Comp Med       Date:  2021-10-05       Impact factor: 0.982

5.  Animal models of HIV peripheral neuropathy.

Authors:  Tricia H Burdo; Andrew D Miller
Journal:  Future Virol       Date:  2014-05-01       Impact factor: 1.831

6.  A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors.

Authors:  Jean-Pierre Louboutin; Lokesh Agrawal; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

7.  Reduced lentivirus susceptibility in sheep with TMEM154 mutations.

Authors:  Michael P Heaton; Michael L Clawson; Carol G Chitko-Mckown; Kreg A Leymaster; Timothy P L Smith; Gregory P Harhay; Stephen N White; Lynn M Herrmann-Hoesing; Michelle R Mousel; Gregory S Lewis; Theodore S Kalbfleisch; James E Keen; William W Laegreid
Journal:  PLoS Genet       Date:  2012-01-26       Impact factor: 5.917

Review 8.  Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications.

Authors:  Jean-Pierre Louboutin; David S Strayer
Journal:  ScientificWorldJournal       Date:  2012-02-01

9.  A veterinary twist on pathogen biology.

Authors:  Massimo Palmarini
Journal:  PLoS Pathog       Date:  2007-02       Impact factor: 6.823

10.  Genetic testing for TMEM154 mutations associated with lentivirus susceptibility in sheep.

Authors:  Michael P Heaton; Theodore S Kalbfleisch; Dustin T Petrik; Barry Simpson; James W Kijas; Michael L Clawson; Carol G Chitko-McKown; Gregory P Harhay; Kreg A Leymaster
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.